Related Experiment Videos
Update on pancreatic cancer
Caio Max S Rocha Lima1, Barbara Centeno
1Assistant Professor of Medicine and Director of Cytopathology, H. Lee Moffitt Cancer Center and University of South Florida, Tampa, Florida, USA. rochalcm@moffitt.usf.edu
Current Opinion in Oncology
|July 20, 2002
Summary
Pancreatic cancer has a poor prognosis, with a 5-year survival rate under 5%. Early diagnosis and novel treatments, including molecular agents, are crucial for improving outcomes in this challenging malignancy.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Pancreatic cancer is a leading cause of cancer mortality globally.
- Late-stage diagnosis frequently limits surgical curative options.
- Current systemic treatments offer limited benefits, particularly in advanced stages.
Purpose of the Study:
- To highlight the challenges in diagnosing and treating pancreatic cancer.
- To emphasize the need for improved diagnostic and therapeutic strategies.
- To note the emergence of molecularly targeted agents in clinical trials.
Main Methods:
- Review of current challenges in pancreatic cancer diagnosis and treatment.
- Discussion of disease biology and its impact on clinical approaches.
- Identification of emerging therapeutic avenues.
Main Results:
- Pancreatic cancer exhibits a dismal 5-year survival rate (<5%).
- Late diagnosis is common, restricting the efficacy of surgery.
- Chemotherapy has a predominantly palliative role in advanced disease.
Conclusions:
- Advances in understanding pancreatic cancer biology are essential for better diagnosis and treatment.
- Molecularly targeted agents represent a promising area for future clinical trials.
- Improved diagnostic tools and therapeutic strategies are urgently needed.